Physician profile
Scott Young
NPI 1821000431
$69,277.84
in general payments reported to CMS, 2019-2025
40 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18K · 2022: $18K · 2023: $14K · 2024: $6,366 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Consulting Fee: $7,423 · Food and Beverage: $5,080 · Travel and Lodging: $4,756 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,442.44 |
| Consulting Fee | $7,422.50 |
| Food and Beverage | $5,079.56 |
| Travel and Lodging | $4,755.92 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23,480.88 | 2022-2025 | |
| Allergan, INC. | $21,978.70 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $12,521.42 | 2023-2025 | Gemtesa, Aptiom |
| Urovant Sciences INC | $2,343.71 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $1,764.52 | 2021-2023 | Xiaflex, Aveed |
| Dendreon Pharmaceuticals LLC | $847.61 | 2021-2025 | Provenge |
| Astellas Pharma US INC | $715.05 | 2021-2025 | Xtandi, Myrbetriq |
| Pfizer INC. | $591.33 | 2021-2025 | |
| Antares Pharma, INC. | $514.24 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Coloplast Corp | $464.39 | 2021-2024 | Speedicath, Titan |
| Axonics, INC. | $425.68 | 2022-2024 | Bulkamid, Axonics |
| Endo USA, INC. | $411.55 | 2024-2025 | Xiaflex, Aveed |
| Janssen Biotech, INC. | $409.96 | 2021-2025 | Erleada |
| Medtronic, INC. | $344.05 | 2022-2024 | Interstim |
| Blue Earth Diagnostics | $279.04 | 2024-2025 | Posluma |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $265.59 | 2022-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Progenics Pharmaceuticals, INC. | $262.51 | 2021-2025 | Pylarify |
| Boston Scientific Corporation | $167.03 | 2021-2023 | Ams 700 Cxr Rte Kit, Rezum Generator |
| Astrazeneca Pharmaceuticals LP | $159.43 | 2021-2022 | |
| Teleflex LLC | $133.54 | 2021-2023 | Urolift |
| Accord Healthcare, INC. | $132.44 | 2024-2025 | |
| 180 Medical, INC. | $128.90 | 2021-2025 | Gentlecath Glide, Gentlecath |
| Merck Sharp & Dohme LLC | $116.64 | 2022-2023 | Lynparza, Keytruda |
| Agiliti Surgical, INC. | $88.04 | 2022 | |
| Myriad Genetic Laboratories, INC. | $84.87 | 2021-2023 | Prolaris |
| Novartis Pharmaceuticals Corporation | $82.33 | 2024-2025 | |
| Calyxo, INC. | $81.59 | 2024 | Cvac Aspiration System |
| Alnylam Pharmaceuticals INC. | $70.80 | 2021-2023 | Givlaari |
| Clarus Therapeutics INC. | $68.46 | 2021 | |
| Urogen Pharma, INC. | $54.89 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.52 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $48.44 | 2022 | |
| Ferring Pharmaceuticals INC. | $47.99 | 2024-2025 | Adstiladrin |
| Hollister Incorporated | $29.24 | 2022 | |
| Myovant Sciences INC. | $23.36 | 2021 | |
| Tolmar, INC. | $20.39 | 2023 | |
| Acerus Pharmaceuticals Corporation | $19.44 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $17.42 | 2021 | |
| Halozyme INC | $17.24 | 2023 | |
| Immunitybio, INC. | $14.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.